Rhythm’s drug shows 25% drop in BMI over one year for pa­tients with rare form of obe­si­ty

Rhythm Phar­ma­ceu­ti­cals’ obe­si­ty drug set­melan­otide showed off a 25.5% re­duc­tion in body mass in­dex af­ter 12 months in adult and pe­di­atric pa­tients with hy­po­thal­a­m­ic obe­si­ty, a rare con­di­tion that caus­es pa­tients to feel ex­treme hunger, ac­cord­ing to new, longer-term Phase II da­ta pre­sent­ed Tues­day at Obe­si­ty­Week.

Set­melan­otide al­so led to a 16% re­duc­tion in mean BMI at three years in adult pa­tients with Bardet-Biedl syn­drome, a rare ge­net­ic dis­or­der that can lead to obe­si­ty, and a 20.3% re­duc­tion in mean BMI at four years in adults with obe­si­ty due to POMC or LEPR de­fi­cien­cy, an­oth­er rare ge­net­ic dis­or­der that stems from gene mu­ta­tions that reg­u­late hunger.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER